Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
PRESS
Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
Biotricity Inc. (Biotricity) today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.
Wedge Networks Inc. (Wedge), a global leader in software defined Orchestrated Real-time Threat Prevention, is pleased to announce its 2021 Audited Consolidated Financial Statements have been released and are now available to shareholders.
Biotricity Inc. (Biotricity) today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI).
Biotricity Inc. (Biotricity), today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD’). The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification schemes do not consider stages of CKD. Additionally, the detection of stroke-risk variations due to dialysis requires real-time risk monitoring, which is unavailable to date.
